Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyFLT3 Inhibitors in Acute Myeloid Leukemia: Increasing Options

In this Clinical Advances in Hematology & Oncology Q&A with Dr. Tapan M. Kadia, an associate professor at the MD Anderson Cancer Center, the current treatments for acute myeloid leukemia (AML) are discussed, with a specific focus on the targeted FLT3 approach, the role of the gene in AML, the differences among the approved FLT3 inhibitors, and why newer FLT3 inhibitors are needed.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form